S-Ketamine is under clinical development by AFYX Therapeutics and currently in Phase II for Cluster Headache Syndrome (Cluster Headache). According to GlobalData, Phase II drugs for Cluster Headache Syndrome (Cluster Headache) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how S-Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

S-Ketamine overview

S-Ketamine is under development for the treatment chronic cluster headache. The drug candidate is administered through intranasal route as spray. It targets N-methyl-D-aspartate (NMDA) receptor.

AFYX Therapeutics overview

AFYX Therapeutics is a biopharmaceutical company engaged in research and development of pharmaceuticals aiming for better treatment of diseases including cancer, women’s health and high-scale pain. The company is headquartered in Horsholm, Denmark.

For a complete picture of S-Ketamine’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.